BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
02 December 2009 - 2:00AM
PR Newswire (US)
ARLINGTON, Va., Dec. 1 /PRNewswire/ -- BioInformatics, LLC
announces the release of its newest report, The Market Outlook for
Research Products in FY2010. The 8.2 billion dollars appropriated
to the NIH Scientific Research program by the American Recovery and
Reinvestment Act (ARRA) is being earmarked for lab renovations,
Challenge Grants, the Shared Instrumentation Program and research
that spans multiple public and non-profit institutions, all of
which will have an immediate and long-term impact on the life
science tools industry. Comprised of responses from scientists with
varying degrees of influence and purchasing authority in the lab,
The Market Outlook for Research Products in FY2010 was designed to
help provide insight as to how labs are going to allocate their
budgets over the next fiscal year, how they are responding to the
economic recession and where they believe their organizations are
headed in FY2011. Researchers predict that their FY2010 budgets
will, on average, be 4.5% higher than their budgets for FY2009. On
the whole, academic respondents foresee slightly larger budget
increases (5.5%), while industrial respondents expect somewhat
smaller budget increases. The Market Outlook for Research Products
in FY2010, includes detailed responses from nearly 800 scientists
about their FY2010 budgets, planned expenditures and sources of
funding. This study compares and contrasts FY2009 (actual) and
FY2010 (projected) budgets in total, and by product category with a
special focus on market segment and regional differences. European
and U.S. scientists are asked about planned purchases of both
consumables and instrumentation, and from what sources they expect
to receive funding, with an emphasis on the ARRA. 61% of the survey
respondents said that either they or someone in their lab applied
for a recovery act grant. In this report, scientists also indicate
planned instrument and consumable purchases by vendor. The
following suppliers were provided as some of the choices in the
survey: Abcam (LSE:ABC.L) Abgene (Thermo Fisher Scientific
(NYSE:TMO)) Affymetrix (NasdaqGS: AFFX) Agilent Technologies BD
Biosciences (NYSE:BDX) Bio-Rad (NYSE:BIO) Beckman Coulter
(NYSE:BEC) BioSource (Life Technologies (NasdaqGS: LIFE))
Calbiochem Millipore (NYSE:MIL) Dako GE Healthcare (Amersham)
(NYSE:GE) Invitrogen Leica Microsystems PerkinElmer (NYSE:PKI)
Qiagen (NasdaqGS: QGEN) Roche Applied Science Sigma-Aldrich
(NASDAQ:SIAL) Waters Corporation "While the overall projections for
growth in researchers' FY2010 research budgets are generally
positive, differences by geographic region and market segment with
respect to funding sources and budget realities will impact not
only the spending practices of various labs, but also their
receptivity to life science suppliers and their marketing and
advertising campaigns," states Tamara Zemlo, Ph.D., MPH, Vice
President of Advisory Services. Dr. Zemlo further notes that
"Suppliers that are sensitive to a researcher's perceptions of the
economy and how it is affecting their science are more likely to
maintain good customer relations if they offer promotions that
specifically address their customers' concerns." To learn more
about this report, a complimentary Executive Summary is available
at http://www.gene2drug.com/reports/205/. ABOUT BIOINFORMATICS, LLC
BioInformatics, LLC is the premier research and advisory firm
serving the life science industry. By leveraging our professional
social network of more than 45,000 biomedical researchers, we have
supported more than 300 companies and provided insights that lead
to better business decisions. Our assignments include assessing the
size and attractiveness of markets, optimizing product
configurations and pricing, validating corporate acquisitions,
measuring customer loyalty, and evaluating brand strength and
positioning. For more information contact: Mary Follin Manager,
Marketing/Sales BioInformatics, LLC 2111 Wilson Blvd., Suite 250
Arlington, VA 22201 703.778.3080 x13 (phone)
http://www.gene2drug.com/ DATASOURCE: BioInformatics, LLC CONTACT:
Mary Follin, Manager, Marketing/Sales of BioInformatics, LLC,
+1-703-778-3080 ext. 13, Web Site: http://www.gene2drug.com/
Copyright